Reuters reported that natural gas mineral and royalty business WhiteHawk filed for a U.S. IPO, disclosing a 615% revenue increase in 2025. The article noted renewed investor interest in U.S. energy assets and included commentary from IPOX® Associate Lukas Muehlbauer: “Royalty businesses can be attractive within the sector because they offer exposure to commodity prices and drilling activity without the same spending burden as traditional oil and gas producers.”

Global IPO activity is accelerating across major regions, led by large technology, infrastructure, and consumer listings. In the U.S., Blackstone’s data center vehicle, Cerebras, Quantinuum, Lime, Odyssey, Applied Aerospace & Defense, and Tenneco highlight strong demand for AI, quantum, biotech, mobility, defense, and industrial deals. Europe is seeing London IPO plans from Barnes & Noble/Waterstones and Dangote Cement, while Asia-Pacific features major Hong Kong and Tokyo listings from Syngenta, Kunlunxin, Three-Circle, Go, Sany Heavy, and SkinKandy this year overall globally.

IPOX® CEO Josef Schuster commented on Quantinuum’s U.S. IPO filing in Reuters’ coverage of the Honeywell-backed quantum computing company’s move toward a Nasdaq listing under QNT. Reuters said Quantinuum reported higher revenue and a wider net loss while still in early commercial growth. Schuster said, “Pursing an IPO is always the first best choice to raising money,” even for high-risk quantum deals, citing the open U.S. IPO window and strong investor endorsement of quantum-linked companies overall.

IPOX® CEO Josef Schuster commented on the strength of the U.S. IPO market in Reuters’ coverage of Applied Aerospace & Defense’s IPO filing. Reuters said the defense hardware provider posted a 24.8% revenue increase in 2025, narrowed its net loss, and plans to list on the NYSE under “AADX.” Schuster said, “The U.S. IPO market is in its best shape I have seen it since the late 1990s,” adding the recovery reflects “strong post-IPO returns” and broad deal reception.

Reuters reported that Odyssey Therapeutics reached a nearly $900 million valuation after shares rose in its Nasdaq debut. IPOX® Research Associate Lukas Muehlbauer said the trend suggests the “biotech IPO window is open again after a lackluster 2025.” He also noted, “In a biotech market where M&A remains an important exit route for recently listed companies, investors may view Glick’s history as adding to Odyssey’s appeal,” citing founder Dr. Gary D. Glick’s biotech track record.

Reuters reports Lime filed for a U.S. IPO, with IPOX® Research Associate Lukas Muehlbauer noting, “Lime’s filing reflects both a better IPO market and a stronger company profile than in the previous years.” He added, “While the underlying picture has improved meaningfully, the main caveat is that the company remains loss-making and investors will look closely at whether they can turn strong revenue numbers into more consistent profitability.” Lime plans to list on Nasdaq under “LIME.”

Reuters reports Blackstone Digital Infrastructure Trust is aiming to raise slightly over $1.7 billion in a U.S. IPO to acquire newly built data centers amid strong demand for AI-linked infrastructure. IPOX® CEO Josef Schuster is quoted on the strength of the U.S. IPO market, noting that gains in AI- and energy-related deal flow have supported sentiment and demand for new listings. The Blackstone vehicle plans to list on the NYSE under the symbol “BXDC.”

Reuters reports Cerebras Systems is targeting a valuation of up to $26.62 billion in its U.S. IPO, amid strong investor demand for AI infrastructure and advanced chips. IPOX® Research Associate Lukas Muehlbauer is quoted on Cerebras’ competitive positioning against Nvidia, its role as a signal deal for high-growth AI infrastructure listings, and the potential race to complete offerings before a major SpaceX IPO draws investor attention and capital in the Reuters article published May 4, 2026.

Global IPO activity remains active across major regions, led by large U.S. listing plans from SpaceX, Roze AI, SK Hynix, Tenneco and Pershing Square USA. Europe’s pipeline includes delayed or potential listings from RAC, Dolomiti Energia and BioMar, while Singapore is advancing dual U.S.-Singapore listing rules. In MENA, Saudi Arabia’s DABS IPO is testing investor confidence amid volatility, highlighting selective resilience despite a sharp regional slowdown in issuance across the wider GCC market.

Reuters reported that Bill Ackman’s Pershing Square and Pershing Square USA are set to list on the NYSE after Pershing Square USA raised $5 billion in its IPO. The debut marks Ackman’s renewed effort to bring a flagship U.S.-listed fund to market and tests investor appetite for closed-end funds. IPOX® Research Associate Lukas Muehlbauer was quoted on the offering’s structure, noting that shares of the managing company may have helped support investor demand beyond the fund alone in the listing.

Reuters reported that Rare Earths Americas launched its U.S. IPO roadshow, targeting a valuation of up to $368.4 million amid rising investor interest in critical minerals. The company plans to raise up to $52.8 million and list on NYSE American under “REA”. IPOX® Associate Lukas Muehlbauer was quoted, noting the company’s role in supply-chain diversification and the potential M&A appeal of newly public rare earth companies in a strategically important sector as global demand continues to accelerate sharply worldwide.

Lincoln International has filed for a rare U.S. initial public offering, joining the ranks of publicly traded boutique investment banks like Moelis and Houlihan Lokey. The Chicago-based firm, which reported $214.1 million in net income on $783.8 million in revenue for 2025, is capitalizing on a rebounding global dealmaking environment. IPOX® CEO Josef Schuster highlighted the asset class's resilience against recent geopolitical volatility, stating a "golden age for U.S. IPOs has arrived" amidst strong demand for U.S.-domiciled specialty deals.

A historic tech IPO wave is building, with giants like SpaceX, OpenAI, and Anthropic targeting a combined $3 trillion valuation, signaling a massive shift in public equities. In the U.S., Milan-based Bending Spoons preps a $20 billion listing, while the new Texas Stock Exchange targets a 2027 launch. European markets remain dynamic; Revolut eyes a staggering $200 billion valuation by 2028, and Boots explores a London float. Meanwhile, geopolitical volatility forced telecom operator Digi to postpone its Spanish debut.

Madison Air achieved a blockbuster $15.65 billion NYSE debut, while biotech firm Kailera Therapeutics surged 62%. The pipeline is expanding rapidly, highlighted by AI chipmaker Cerebras targeting a $35 billion valuation alongside major filings from Inspire Brands, Kraken, and EagleRock. As IPOX® experts note, defense tech and software sectors remain robust. Internationally, Syngenta prepares for a massive $10 billion Hong Kong IPO, and Uzbekistan’s sovereign fund secures BlackRock for its upcoming London listing.

Blackstone-backed mobile app marketing firm Liftoff has officially filed for a U.S. IPO on the Nasdaq under the ticker "LFTO." The company previously paused its listing plans amid market volatility but is now capitalizing on a broader rebound in technology stocks and easing geopolitical tensions. IPOX® Research Associate Lukas Muehlbauer provided expert commentary to Reuters, noting that Liftoff is strategically utilizing this reopening IPO window as investors view the recovering software space as increasingly attractive for new equity listings.

IPOX® Research Associate Lukas Muehlbauer was featured in a recent Reuters article discussing Kailera Therapeutics' $625 million IPO. As shares surged 62.5%, the debut signals a potential biotech IPO market turnaround. Muehlbauer highlighted the strong demand for GLP-1 companies, stating, "Obesity remains one of the few areas in biotech with clear investor appetite." He noted near-term trading relies heavily on broader obesity-drug space fundamentals.